Herceptin moves from IV to subcutaneous (2013–2019)
Roche turned its breast cancer blockbuster Herceptin into a five-minute subcutaneous injection, approved in Europe in 2013 and the US in 2019. The shift cut administration time from roughly 90 minutes to minutes and let some patients get treatment at home.
Subcutaneous Herceptin captured a large share of the patient base in Europe within a few years.
It proved a major biologic could move from IV to home injection without losing efficacy, setting the template for drug delivery innovation.
IQLIK follows the same playbook for Alzheimer's — the identical drug molecule in a more convenient format.
